Travis Mathewson,
Principal Scientist
Travis Mathewson is a principal scientist who currently manages the Automation & Data Support group within the Compound Management & Distribution Group, which delivers continuous improvement solutions for automated sample management workflows. This includes: inventory, tracking, metrics, data curation, automated instrument monitoring, instrument quality control, troubleshooting, and custom solutions. Travis started his career with Pfizer in 1995 in the high-throughput screening (HTS) group. In addition to high-throughput screening he managed the Pfizer HTS screening compound collections and helped to build automated screening workflows. In July of 1999, he received the Pfizer Central Research Achievement Award for pace-setting contributions to Exploratory Medicinal Science’s technology leadership and effectiveness, achieved by applying high-throughput methodologies to enhance productivity. In collaboration with Evotec from 2001 to 2006, he applied innovative nanoliter technology in high density 1,536 and 2,080 well plates to enable ultra-high through-put screening (uHTS) in single microliter or less total assay screening volumes. During this time, his scientific efforts contributed towards a publication in the September 2005, vol.10, no. 6 edition of the Journal of Biomolecular Screening entitled ‘NanoStore: A Concept for Logistical Improvements of Compound Handling in High-Throughput Screening’. The innovative nanostore concept was a scientific breakthrough for compound handling techniques which was crucial towards enabling uHTS on the Evotec platform. In March of 2001 and February of 2003, he received the Pfizer Discovery Research Initiative Award for enhancing the compound registration process and for spearheading the implementation of innovative automation technology into HTS workflows. In 2005, he was put in charge of the Groton Plate Provisioning Group where he hired a team of individuals and coordinated with the Sandwich Plate Provision Group to support the compound handling needs of the global HTS group by providing assay ready plates (ARPs) for screening and by maintaining the Pfizer compound screening libraries.
|
|
|
